A. Kalita

发表

Two Polymorphic Variants of Wild-Type p53 Differ Biochemically and Biologically

Miranda Thomas, A. Kalita, S. Labrecque, 1999, Molecular and Cellular Biology.

Substituted N-(2-aminophenyl)-benzamides, (E)-N-(2-aminophenyl)-acrylamides and their analogues: novel classes of histone deacetylase inhibitors.

A. Kalita, A. Macleod, O. Moradei, 2006, Bioorganic & medicinal chemistry letters.

4-(Heteroarylaminomethyl)-N-(2-aminophenyl)-benzamides and their analogs as a novel class of histone deacetylase inhibitors.

A. Kalita, M. Robert, O. Moradei, 2008, Bioorganic & medicinal chemistry letters.

MGCD0103, a novel isotype-selective histone deacetylase inhibitor, has broad spectrum antitumor activity in vitro and in vivo

Sylvain Lefebvre, Daniel Delorme, A. Kalita, 2008, Molecular Cancer Therapeutics.

Development of potential antitumor agents. Synthesis and biological evaluation of a new set of sulfonamide derivatives as histone deacetylase inhibitors.

Daniel Delorme, A. Kalita, M. Robert, 2003, Journal of medicinal chemistry.

Phase I trials of the oral histone deacetylase (HDAC) inhibitor MGCD0103 given either daily or 3x weekly for 14 days every 3 weeks in patients (pts) with advanced solid tumors

K. Gelmon, A. Tolcher, M. Carducci, 2005 .

Evaluation of the Pharmacodynamic Effects of MGCD0103 from Preclinical Models to Human Using a Novel HDAC Enzyme Assay

M. Carducci, L. Siu, A. Kalita, 2008, Clinical Cancer Research.

Phase I study of MGCD0103 given as a three-times-per-week oral dose in patients with advanced solid tumors.

M. Carducci, L. Siu, A. Kalita, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase 1 study of the oral isotype specific histone deacetylase inhibitor MGCD0103 in leukemia.

M. Minden, Z. Estrov, W. Miller, 2008, Blood.

SAR and biological evaluation of analogues of a small molecule histone deacetylase inhibitor N-(2-aminophenyl)-4-((4-(pyridin-3-yl)pyrimidin-2-ylamino)methyl)benzamide (MGCD0103).

A. Kalita, O. Moradei, S. Leit, 2009, Bioorganic & medicinal chemistry letters.

Phase I study of isotype-selective histone deacetylase (HDAC) inhibitor MGCD0103 given as three-times weekly oral dose in patients (pts) with advanced solid tumors.

R. Sullivan, M. Carducci, L. Siu, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Pharmacodynamic effect of MGCD0103, an oral isotype-selective histone deacetylase (HDAC) inhibitor, on HDAC enzyme inhibition and histone acetylation induction in phase I clinical trials in patients (pts) with advanced solid tumors or non-Hodgkin’s lymphoma (NHL)

K. Gelmon, A. Tolcher, M. Carducci, 2005 .

Evaluation of the Pharmacodynamic Effects of MGCD 0103 from Preclinical Models to Human Using a Novel HDAC

M. Carducci, L. Siu, A. Kalita, 2008 .

Role of a p53 polymorphism in the development of human papilloma-virus-associated cancer

Irene M. Leigh, Catherine A. Harwood, Judith Breuer, 1998, Nature.

Sulfonamide anilides, a novel class of histone deacetylase inhibitors, are antiproliferative against human tumors.

A. Kalita, A. Macleod, S. Leit, 2002, Cancer research.

(2-Amino-phenyl)-amides of ω-substituted alkanoic acids as new histone deacetylase inhibitors

A. Kalita, A. Macleod, O. Moradei, 2004 .

Discovery of N-(2-aminophenyl)-4-[(4-pyridin-3-ylpyrimidin-2-ylamino)methyl]benzamide (MGCD0103), an orally active histone deacetylase inhibitor.

Isabelle Paquin, Daniel Delorme, A. Kalita, 2008, Journal of medicinal chemistry.

A phase I study of MGCD0103 given as a twice weekly oral dose in patients with advanced leukemias or myelodysplastic syndromes (MDS)

A. Kalita, J. Lancet, M. Ward, 2007 .

(2-amino-phenyl)-amides of omega-substituted alkanoic acids as new histone deacetylase inhibitors.

A. Kalita, A. Macleod, O. Moradei, 2004, Bioorganic & medicinal chemistry letters.

Design and synthesis of 4-[(s-triazin-2-ylamino)methyl]-N-(2-aminophenyl)-benzamides and their analogues as a novel class of histone deacetylase inhibitors.

A. Kalita, M. Robert, A. Macleod, 2008, Bioorganic & medicinal chemistry letters.

Phase 1 study of the oral isotype specific histone deacetylase inhibitor MGCD0103 in leukemia.

M. Minden, Z. Estrov, W. Miller, 2008, Blood.

MGCD0103, a novel isotype-selective histone deacetylase inhibitor, has broad spectrum antitumor activity in vitro and in vivo

A. Kalita, M. Robert, A. Macleod, 2008, Molecular Cancer Therapeutics.

Phase I/II: The oral isotype-selective HDAC inhibitor MGCD0103 in combination with gemcitabine (Gem) in patients (pts) with refractory solid tumors

H. Hurwitz, E. Chan, B. Nelson, 2007 .